PUNE, India, March 9, 2016 /PRNewswire/ --
Market research report titled "Atherosclerosis - Pipeline Review, H2 2015" provides an overview of the Atherosclerosis's therapeutic pipeline and enhances decision making capabilities to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Company Profiles discussed in this report includes Ache Laboratorios Farmaceuticos S/A, advanceCor GmbH, AFFiRiS AG, Arisaph Pharmaceuticals, Inc., Artery Therapeutics, Inc., AstraZeneca Plc, Athera Biotechnologies AB, AtheroNova Inc., Bayer AG, Campus Technologies Freiburg GmbH, Cardax Pharmaceuticals, Inc., Cerenis Therapeutics Holding SA, ChemoCentryx, Inc., CohBar, Inc., Daiichi Sankyo Company, Limited, DoNatur GmbH, Dybly AG, Exicure, Inc., F. Hoffmann-La Roche Ltd., GenKyoTex S.A., Gilead Sciences, Inc., Jenrin Discovery, Inc., Johnson & Johnson, KineMed, Inc., Kowa Company, Ltd., La Jolla Pharmaceutical Company, Lead Discovery Center GmbH, Merck & Co., Inc., MI.TO. Technology S.r.L., Omeros Corporation, OPKO Health, Inc., Otsuka Holdings Co., Ltd., Provid Pharmaceuticals, Inc., Resverlogix Corp., The Medicines Company, Therapix Biosciences Ltd, Tolerys SA, Vascular Biogenics Ltd., Vericel Corporation, Virocan Therapeutics Private Limited and Vitae Pharmaceuticals, Inc.
Complete report on H2 2015 pipeline review of Atherosclerosis with 68 market data tables and 15 figures, spread across 258 pages is available at http://www.reportsnreports.com/reports/461984-atherosclerosis-pipeline-review-h2-2015.html
Drugs Profiles discussed in this report includes 6860766, AEM-28, AG-01, AHRO-001, AHRO-002, AHRO-003, AM-0010, AmVidcm-009, anacetrapib, Annexin A-5, apabetalone, ARI-1778, Artpep-2, ATH-03, ATH-04, ATH-05, ATH-06, AZ-876, BAY-606583, BSN-272, CCX-771, CDX-085, Cell Therapy for Atherosclerosis, Cellular Immunotherapy for Atherosclerosis, CER-209, CM-7, COR-2, D-4F, DIAS-2, Drug for Atherosclerosis, Drugs to Activate TLR3 for Atherosclerosis, Drugs to Antagonize NMDA Receptor for Atherosclerosis, DYB-186, EP-80317, FX-5A, Gene Therapy for Arteriosclerosis and Endothelial Dysfunction, Gene Therapy to Activate Interleukin 10 for Atherosclerosis, Gene Therapy to Target miR-145 for Atherosclerosis, GKT-831, GYY-4137, Humanin, INV-88, ISIS-APOARx, ITP-01, ixmyelocel-T, JD-2000 Series, JD-5000 Series, JD-6000 Series, K-312, K-877, KM-011, KRP-206, leucine + niacin, LJPC-6417, LPC-01, MCS-18, MDCO-216, melittin, Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases, Monoclonal Antibody to Inhibit Endothelial Lipase for Atherosclerosis, Oligonucleotide for Hyperlipidemia and Atherosclerosis, Oligonucleotides to Agonize SRB1 for Atherosclerosis and Lymphoma, P-16, PC-mAb, Peptides to Inhibit Calcineurin for Rheumatoid Arthritis and Atherosclerosis, PR-15, Protein for Cardiovascular Diseases, Px-102, Recombinant Protein for Atherosclerosis, Recombinant Protein for Atherosclerosis and Hepatic Steatosis, Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis, RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis, RO-6836191, rPAI-123, Small Molecule for Atherosclerosis, Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology, Small Molecule to Agonize Liver X Receptor for Atherosclerosis, Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders, Small Molecule to Target GPR132 for Atherosclerosis, Small Molecule to Target GPR176 for Atherosclerosis, Small Molecules for Atherosclerosis, Small Molecules for Inflammatory Diseases, Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders, Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity, Small Molecules to Inhibit Chymase for Atherosclerosis, Small Molecules to Inhibit Lipase for Atherosclerosis, SPX-7233801, SR-9009, Stem Cell Therapy for Atherosclerosis, Synthetic Peptide to Inhibit F11R for Atherosclerosis, Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease, Synthetic Peptides for Oncology, Sepsis and Atherosclerosis, Synthetic Peptides to Activate Apolipoprotein for Atherosclerosis and Inflammation, Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration, Vaccine for Atherosclerosis, VB-201 and VTP-4.
Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=461984
This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects.
The report provides a snapshot of the global therapeutic landscape of Atherosclerosis. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and also key players involved in the therapeutics development for Atherosclerosis and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects.
Explore more reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
+ 1 888 391 5441
Copyright©2016 PR Newswire.
All rights reserved